Skip to main content
All lobbying filings

CAPITOL HILL CONSULTING GROUP

CAPITOL HILL CONSULTING GROUP filed a Q2 report for PURDUE PHARMA LLP on July 21, 2025, reporting $50,000 in lobbying income.

Lobbying for PURDUE PHARMA LLP

All filings by CAPITOL HILL CONSULTING GROUP · Everything PURDUE PHARMA LLP has reported

 Amended
The filer submitted a later report covering this same period, so the amounts here have been replaced. Site totals count only the latest version. See the current filing, posted Jul 21, 2025.
 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 21, 2025
Income
$50,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 3
  • BRIAN SUTTER
    Previously held: Staff Dir., W&M Health Subcommittee, Chairman Dave Camp April, 2013 - Dec. 2014; Professional Staff, W&M Health Subcommittee, Chairman Dave Camp, Jan. 2011 - April 2013;Leg Dir., Rep. Dave Camp, May '08 - Jan.,'11 Leg Asst.Rep Camp, Feb '03-May'08;
  • EMILY ELIZABETH WILKINSON-HOLLAND New on this filing
    Previously held: Staff -Rep. Price (2010-11), LA: Rep. Grimm (2011-12), Rep. Black (2012-13), Sen.Vitter (2013-2015), Sen. Heller (2015-17), Policy Adv. to the Sec.- Dept of HHS (3/2017-8/2017), Sr Advisor to Administrator - Ctrs for Medicare & Medicaid (8/17- 5/19)
  • CHRISTOPHER DAVIS New on this filing
    Previously held: Staff Assistant, Legislative Assistant, Senior Legislative Assistant, and Legislative Director - Rep. Rick Boucher (2006-2011.

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2
Health Issues

Monitoring for issues and hearing related to prevention of abuse, misuse or diversion of prescription drugs; prescription drug payment reform; and pharmaceutical supply chain.

Bankruptcy

Monitored congressional efforts around the SACKLER Act.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem